Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $177.96M.
ENTERPRISE VALUE (EV)
$177.96M
Prelude Therapeutics Incorporated
Market Cap
$213.21M
Enterprise Value (EV)
$177.96M
Market Cap
$216.34M
Enterprise Value (EV)
$208.57M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $213.21M | $177.96M |
| Niagen Bioscience Inc (NAGE)vs › | $213.44M | $149.03M |
| Alector, Inc. (ALEC)vs › | $211.48M | $184.32M |
| Compugen Ltd. (CGEN)vs › | $211.33M | $204.07M |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.34M | $208.57M |
| Sionna Therapeutics, Inc. (SION)vs › | $208.32M | $153.07M |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.04M | $124.29M |
| Pro-Dex, Inc. (PDEX)vs › | $207.29M | $217.19M |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $220.74M | $184.69M |
Market Cap
$213.21M
Total Debt
$0.00
Cash
$35.26M
Enterprise Value
$177.96M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
